NeoGenomics, Inc.: RaDaR Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

Data presented at this year's San Antonio Breast Cancer Symposium builds on strong base of evidence supporting promise of RaDaR in helping prevent recurrence and improving outcomesFT. MYERS, FL / ACCESSWIRE

Related Keywords

Toronto ,Ontario ,Canada ,Fort Myers ,Florida ,United States ,Georgia ,Tampa ,North Carolina ,United Kingdom ,Texas ,Research Triangle Park ,Atlanta ,China ,California ,San Diego ,San Antonio ,Tennessee ,Singapore ,Houston ,Aliso Viejo ,Cambridge ,Cambridgeshire ,Switzerland ,David Cescon ,Williamb Bonello ,Vishal Sikri ,Cancer Research United Kingdom Cambridge Institute ,Neogenomics Inc ,Inivata Limited ,Neogenomics Inc View ,Company Pharma Services Division ,Nasdaq ,Princess Margaret Cancer Centre ,University Of Cambridge ,University Of Toronto ,Company Annual Report On Form ,Pharma Services ,Department Of Medicine ,San Antonio Breast Cancer Symposium ,Annual San Antonio Breast Cancer Symposium ,Chief Commercial Officer ,Medical Oncology ,Radar Assay ,Breakthrough Device Designation ,Pharma Services Division ,Privacy Practices ,Annual Report ,Inc View ,Neogenomics ,Radar ,Essay ,Emonstrates ,Linical ,Potential ,Detecting ,Disease ,Recurrence ,Cross ,Types ,Early ,Breast ,Dancer ,Ncluding ,Triple ,Negative ,